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A 10-cM genomewide scan of 94 families with hereditary prostate cancer, including 432 affected men, was used
to identify regions of putative prostate cancer–susceptibility loci. There was an average of 3.6 affected, genotyped
men per family, and an overall mean age at diagnosis of 65.4 years. A total of 50 families were classified as early
onset (mean age at diagnosis !66 years), and 44 families were classified as later onset (mean age at diagnosis 66
years). When the entire data set is considered, regions of interest (LOD score1.5) were identified on chromosomes
10, 12, and 14, with a dominant model of inheritance. Under a recessive model LOD scores 1.5 were found on
chromosomes 1, 8, 10, and 16. Stratification by age at diagnosis highlighted a putative susceptibility locus on
chromosome 11, among the later-onset families, with a LOD score of 3.02 (recombination fraction 0) at marker
ATA34E08. Overall, this genomic scan suggests that there are multiple prostate cancer loci responsible for the
hereditary form of this common and complex disease and that stratification by a variety of factors will be required
for identification of all relevant genes.
Introduction
Prostate cancer is the most common solid tumor and the
second leading cause of cancer deaths among men in the
United States. In 2000, ∼180,400 men will be diagnosed
with prostate cancer, and 31,900 will die of the disease
(Greenlee et al. 2000). Case-control, cohort, and twin
studies (Steinberg et al. 1990; Gro¨nberg et al. 1994,
1996; Whittemore et al. 1995; Page et al. 1997), as well
as segregation analyses (Carter et al. 1992; Gro¨nberg et
al. 1997a; Schaid et al. 1998), all suggest strong evidence
for prostate cancer–susceptibility genes in the popula-
tion. Although data from two studies are most consis-
tent with an X-linked or recessive model of inheritance
(Monroe et al. 1995; Narod et al. 1995), three inde-
pendent segregation analyses (Carter et al. 1992; Gro¨n-
berg et al. 1997a; Schaid et al. 1998) support an au-
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tosomal dominant model of inheritance. Dominant al-
leles are estimated to have a low population frequency
(0.36%–1.67%) and to account for ∼9% of all prostate
cancer cases at age 85 years and for as much as 43%
of disease at age55 years (Carter et al. 1992; Gro¨nberg
et al. 1997a; Schaid et al. 1998). The autosomal dom-
inant alleles are hypothesized to be highly penetrant; by
age 85 years, 63%–89% of men carrying a mutation
are likely to incur a clinical diagnosis of disease (Carter
et al. 1992; Gro¨nberg et al. 1997a; Schaid et al. 1998).
To date, genomewide screens of families with prostate
cancer have identified four chromosomal regions of pu-
tative linkage. The first, a locus on chromosome 1q24-
25, termed “HPC1” (MIM 601518), was originally
proposed to account for disease in 34% of families with
prostate cancer in a data set defined by families with
three or more first-degree affected relatives, prostate
cancer in three generations, or two affected siblings di-
agnosed at age 60 years (Smith et al. 1996). Addi-
tional studies suggest that families most likely to have
linkage to the HPC1 locus have an early mean age at
diagnosis (!65 years), four or more close relatives with
the disease, and proportionately more advanced-stage
disease (Gro¨nberg et al. 1997b, 1999). Although two
studies provide weak confirmatory evidence of linkage
to HPC1 (Cooney et al. 1997; Hsieh et al. 1997), several
others, using large data sets comparable to those used
to map HPC1, report no evidence of linkage in any
stratified subset of families (McIndoe et al. 1997; Ber-
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thon et al. 1998; Eeles et al. 1998; Berry et al. 2000;
Goode et al.2000). A combined analysis of 772 families
has suggested that 6% of families with hereditary pros-
tate cancer have linkage to HPC1 (Xu 2000). A second
prostate cancer–susceptibility locus, PCAP (MIM
602759), at 1q 42.2-43, was reported in 1998 by Ber-
thon and colleagues (Berthon et al. 1998). Three other
studies of this region found no or only weak evidence
for linkage (Gibbs et al. 1999a; Whittemore et al. 1999;
Berry et al. 2000). Significant linkage to a third pros-
tate cancer–susceptibility locus, at Xq27-28, termed
“HPCX” (MIM 300147), was identified using a set of
360 Finnish, Swedish, and North American families (Xu
et al. 1998), and the results of two independent studies,
of 153 and 186 families, were consistent with linkage
to this locus in families that show likely maternal in-
heritance of prostate cancer (Lange et al. 1999; Peters
et al., in press). Finally, linkage to a fourth prostate
cancer–susceptibility locus, at chromosome 1p36, has
been reported in families with a history of both prostate
and primary brain cancers (Gibbs et al. 1999b). Sup-
portive evidence for this locus, termed “CAPB” (MIM
603688), has been reported in families with early-onset
prostate cancer, regardless of family history of brain
cancer (M. Badzioch, G. Leblanc, R. Eeles, W. D. Foul-
kes, J. Hopper, S. Edwards, and D. Goldgar, unpub-
lished data).
The lack of strong confirmatory evidence of linkage
for susceptibility loci described thus far, even in studies
using seemingly similar prostate cancer data sets, high-
lights the difficulties in mapping genes associated with
a disease that is both complexly inherited and common.
Multiple prostate cancer–susceptibility genes clearly ex-
ist, and the presence of both genetic and sporadic cases
within single families makes linkage analysis difficult
(Jarvik et al. 1999). In our own data set of families at
high risk for prostate cancer, we have observed, at best,
modest evidence of linkage to any of the loci mentioned
above, with the four loci, in aggregate, likely accounting
for only a small portion of the total incidence of the
disease (McIndoe et al. 1997; Gibbs et al. 1999a, 1999b;
Goode et al. 2000; Peters et al., in press). This, together
with the collective observations in this field of research,
suggests that additional prostate cancer loci remain to
be found. In this report, we summarize our results from
a complete genomewide screen of 94 families with pros-
tate cancer.
Subjects and Methods
Selection of Families with Prostate Cancer
Families in this genome screen were participants in the
Prostate Cancer Genetic Research Study (PROGRESS).
This Seattle-based study ascertained families with three
or more first-degree relatives with prostate cancer, three
generations with prostate cancer, or two first-degree rel-
atives with prostate cancer diagnosed at age !65 years.
Eligible families were recruited through national adver-
tising of a toll-free number (1-800-777-3035) for self-
referrals and communications with urologists, prostate
cancer support groups, and other health-related pub-
lications. Participating family members were enrolled
from throughout North America and several other coun-
tries. Details, including blood collection and DNA iso-
lation, have been reported elsewhere (McIndoe et al.
1997). The institutional review board of the Fred Hutch-
inson Cancer Research Center approved all study pro-
cedures and material.
Markers and Genotyping
A total of 380 microsatellite markers from the Human
Screening Sets 6 and 8 (Research Genetics) were ana-
lyzed. The mean marker heterozygosity was .7. Map
distances were from the 1998 Marshfield Medical Re-
search Foundation map (Broman et al. 1998; also see
the Center for Medical Genetics, Marshfield Medical Re-
search Foundation, Web site). The average spacing be-
tween markers was 9.4 cM, with 99.1% of the contained
distance being !7.5 cM from a marker. When distances
to terminal map markers are included, 97.1% of the
Marshfield map is !7.5 cM, and 98.9% is !10 cM, of
a marker included in this analysis. PCR amplification
and genotyping has been described elsewhere (Gibbs et
al. 1999b).
Statistical Methods
PedCheck 1.1 (O’Connell and Weeks 1998) and Un-
known from the ANALYZE software package (Well-
come Trust Center for Human Genetics) were used to
test the data set for Mendelian errors. Because the ma-
jority of pedigrees contained ungenotyped founders,
and, consequently, rare alleles of many markers were
present only in nonfounders, allele frequencies were es-
timated from all genotyped individuals by the use of
downfreq from ANALYZE. In this data set of 94 fam-
ilies, the maximum contribution to the total pool of
genotypes from related individuals in any single family
was !2.5% of genotypes. Thus, we expected that fre-
quencies calculated from the entire data set would not
differ significantly from frequencies calculated from a
data set of unrelated individuals, not accounting for any
racial differences. The ANALYZE software package and
the FASTLINK 4.1P version of LINKAGE (Lathrop et
al. 1984; Cottingham et al. 1993) were used for the two-
point parametric analysis. Multipoint parametric and
nonparametric linkage (NPL) analyses used GENE-
HUNTER version 1.2 (Kruglyak et al. 1996).
The genetic model (age- and genotype-specific pene-
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Table 1
Characteristics of 94 Families with Prostate Cancer, by Mean Age at Diagnosis
OVERALL
MEN WHOSE MEAN
AGE AT DIAGNOSIS WAS
(years)
!66 years 66 years
No. of families 94 50 44
No. of affected men sampleda 340 185 155
Average no. of affected men sampled/family 3.6 (2–12) 3.7 3.5
Mean age at diagnosis of affected men sampled (range) 65.4 years (42– 85 years) 62.3 years 69.1 years
a Includes one affected man who was surveyed but who did not provide a blood sample.
trance) used for LOD-score analysis followed the
method of Easton et al. (1995) and defined 11 liability
classes for a rare ( ) dominant gene. This modelq = .003
exactly follows model B of Gro¨nberg et al. (1997c), ex-
cept for the addition of a nonsusceptible liability class
for women and unaffected men of age !30 years. Lia-
bilities for gene carriers also were as in model B of Gro¨n-
berg et al. (1997c), culminating with a lifetime risk of
88%. These risks are based on segregation analysis of
familial prostate cancer ascertained through patients
undergoing prostatectomy (Carter et al. 1992). For
non–gene carriers, the risk increased with age, to a max-
imum of 16%. In this model, penetrance ratios (i.e., gene
carriers/non–gene carriers) decreased from 47 for af-
fected men under 50 years of age to 1.7 for men diag-
nosed at age 80 years. The corresponding ratios for
unaffected men were 48.4 and 5.5. This model was
adapted for X-linked inheritance, for the scan of the X
chromosome. Because repeating a parametric linkage
scan under both a dominant and recessive model has
been proposed as a method to avoid false negatives due
to model misspecification (Greenberg et al. 1998), a re-
cessive model also was tested. For this purpose, we im-
plemented the recessive model reported by Carter et al.
(1993), which specifies a disease-allele frequency of .341,
with lifetime penetrance of 79% in homozygote carriers,
and a lifetime risk of 25% for men of age 130 years
who have other genotypes.
Results
Two-Point Analysis
The 94 families in this study included 1,517 individ-
uals. There were 432 affected men, of which 340 were
surveyed and 339 provided blood samples. There was
an average of 3.6 affected men per family (range 2–12).
The age at diagnosis of surveyed affected men was 42–85
years (mean 65.4 years) (table 1). Ninety of the 94 fam-
ilies are White. Diagnosis was confirmed by medical re-
cords for 333 of the 340 affected men (97.9%); records
for the remaining 7 were unavailable.
The 94 families were analyzed as a single set and then
were stratified by mean age at diagnosis, which was de-
fined a priori by use of the mean ages at diagnosis of
the affected men in each family. This resulted in data
sets of 50 families in which the mean age at diagnosis
was !66 years (early-onset families) and 44 families in
which the mean age at diagnosis was 66 years (later-
onset families). Within the 50 early-onset families, there
was a subset of 16 families in which the mean age at
diagnosis was !61 years (earliest-onset families).
Dominant Model
Three regions of interest, which had two-point LOD
scores 1.5, were defined in a genomewide scan of 94
families, by use of the dominant model (fig. 1 andtable
2). On chromosome 12, a LOD score of 1.76 (recom-
bination fraction [v] .14) was observed with marker
D12S1045. Flanking markers several centimorgans cen-
tromeric to D12S1045 also were positive, although the
closest telomeric marker (D12S392), which is !1 cM
from D12S1045, was not. When considered alone, the
50 early-onset families (mean age at diagnosis !66 years)
gave a LOD score of 1.89 at (fig. 2).v = .10
A second region of interest, located on chromosome
10, was defined by a LOD score of 1.68 ) at(v = .08
marker D10S1223 (fig. 1). Markers flanking D10S1223
were positive, with a LOD score of 0.91 observed at
marker D10S1237 ( ), which is located 21.6 cMv = .18
centromeric to D10S1223. The 50 early-onset families
contributed disproportionately to the result, with a LOD
score of 2.35 ( ).v = .02
A LOD score of 1.74 ( ) with marker D14S588v = .10
defined the final region of interest under the dominant
model in the 94-family data set. Markers flanking
D14S588 were positive only at high values of v. As with
the other regions of interest, stratification by age at di-
agnosis indicated that the majority of likely linked fam-
ilies were early onset (upper section oftable 2).
Additional regions of interest with LOD scores 1.5
in stratified subsets of the families were identified on
chromosomes 6, 9, and 11 (figs. 2 and 3). The strongest
result seen for any analysis and any stratification was
on chromosome 11, where a LOD score of 3.02 (v =
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Figure 1 Two-point LOD scores of total data set, dominant and recessive models. Maximum LOD scores for each marker are plotted
in order of chromosomal position.
) was observed in the 44 later-onset families, at.00
marker ATA34E08 (fig. 3). Flanking markers were pos-
itive and included a LOD score of 1.02 at D11S1999.
Only low LOD scores were observed, however, in either
the total data set or the early-onset stratifications (upper
section oftable 2). The majority of the LOD score in the
later-onset men was contributed by 25 families whose
mean age at diagnosis was 66–69 years (LOD score
2.56).
Recessive Model
The genome screen was also analyzed under a reces-
sive model. Two-point LOD scores 1.5 were seen on
chromosomes 1, 8, 10, and 16 in the total data set (fig.
1) and on chromosomes 2, 11, 12, and 15 in the age-
stratified groups (figs. 2 and 3 and the lower section
oftable 2). The largest LOD score in the 94 families was
at D10S1223, with a maximum of 2.46 ( ) (lowerv = .04
section oftable 2). Three regions previously identified in
the dominant analysis also were seen when the recessive
model was used. Of these, the LOD score at D10S1223
was higher with the recessive model, and LOD scores at
ATA34E08 and D12S1045 were lower. At D8S2324,
with LOD scores of 2.17 ( ) in all families andv = .10
2.05 ( ) in the later-onset families when the reces-v = .00
sive model was used, the corresponding LOD scores for
the dominant model were 0.75 ( ) and 1.47 (v = .20 v =
). The other results, on chromosomes 1, 2, 15, and.02
16 (lower section oftable 2), are unique to the recessive
model.
Multipoint Analysis
Multipoint NPL analyses of the total data set, by
GENEHUNTER (Kruglyak et al. 1996), highlighted
four regions with . Two of these, at D10S1223P ! .10
(NPL 1.61; ) and ATA34E08 (NPL 1.30;P = .057 P =
) corresponded to regions also identified by the.099
two-point parametric analyses. Multipoint analyses of
these two regions revealed a peak NPL score of 1.45
( ) at D10S1223 in the early-onset families and aP = .08
peak NPL of 1.90 ( ) at ATA34E08 in the later-P = .03
onset families. The two further regions found in the total
data set were an NPL peak of 1.48 ( ) betweenP = .073
markers D3S1744 and D3S1763 on 3q (this peak in-
creased to 1.72 [ ] for later- onset families)P = .048
and an NPL peak of 1.45 ( ) at the position ofP = .077
marker D1S1597 in the putative CAPB region. Age
group–specific multipoint analysis of the CAPB region
Table 2
Two-Point and Multipoint LOD Scores, for Dominant and Recessive Models, and NPL Scores for All Regions of
Interest (Two-point LOD Score 1.5)




LOD v LOD HLOD a NPL P
Dominant:
D12S1045 (160.7 cM):
All (94) 1.76 .14 3.29 .57 .26 .48 .31
!66 years (50) 1.89 .10 1.66 .57 .31 .72 .23
66 years (44) .09 .26 1.62 .04 .16 .07 .52
!61 years (16) 1.05 .04 .05 .30 .50 .58 .27
D14S588 (75.6 cM):
All (94) 1.74 .10 2.21 .71 .31 .43 .33
!66 years (50) 1.03 .10 1.97 .36 .27 .70 .24
66 years (44) .71 .08 .25 .38 .41 .12 .54
!61 years (16) 1.68 .00 .61 .17 .34 .67 .25
D10S1223 (156.3 cM):
All (94) 1.68 .08 1.32 .96 .39 1.61 .06
!66 years (50) 2.35 .02 1.41 1.79 .69 1.45 .08
66 years (44) .00 .50 2.73 .00 .01 .81 .21
!61 years (16) .51 .00 1.00 1.00 .93 .61 .26
ATA34E08b (33.0 cM):
All (94) .65 .18 2.91 .29 .25 1.30 .10
!66 years (50) .00 .50 4.02 .00 .01 .01 .48
66 years (44) 3.02 .00 1.12 1.14 .82 1.89 .03
!61 years (16) .17 .18 .52 .14 .37 .33 .36
D9S925 (32.2 cM):
All (94) .04 .30 4.08 .03 .08 .21 .41
!66 years (50) .72 .12 1.36 .27 .28 .67 .24
66 years (44) .00 .50 2.72 .00 .00 .41 .65
!61 years (16) 1.60 .00 1.14 1.14 1.00 1.43 .08
D6S1019 (53.8 cM):
All (94) .03 .36 4.24 .28 .19 .49 .30
!66 years (50) .00 .50 5.55 .00 .00 .52 .69
66 years (44) 1.62 .00 1.31 1.35 .79 1.28 .10
!61 years (16) .00 .50 1.83 .00 .00 .04 .50
Recessive:
D10S1223 (156.3 cM):
All (94) 2.46 .04 .23 1.15 .48 1.61 .06
!66 years (50) 1.28 .06 .68 1.02 .62 1.45 .08
66 years (44) 1.17 .02 .91 .26 .31 .81 .21
!61 years (16) .35 .02 .08 .26 .54 .61 .26
D8S2324 (94.1 cM):
All (94) 2.17 .10 3.92 .18 .16 .05 .51
!66 years (50) .51 .18 4.17 .00 .00 1.00 .84
66 years (44) 2.05 .00 .25 .82 .50 1.00 .16
!61 years (16) .04 .26 1.54 .00 .00 .06 .46
D1S1656 (245.1):
All (94) 1.99 .12 5.26 .05 .09 .33 .36
!66 years (50) 1.46 .10 2.87 .01 .02 .01 .48
66 years (44) .61 .16 4.23 .00 .01 .45 .66
!61 years (16) .30 .10 1.63 .00 .00 1.24 .90
D16S748 (22.7 cM):
All (94) 1.58 .12 2.68 .28 .23 1.12 .13
!66 years (50) 1.22 .10 1.40 .13 .22 .80 .21
66 years (44) .42 .18 1.28 .15 .25 .78 .21
!61 years (16) .10 .12 1.20 .00 .00 .53 .69
(continued)
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Table 2 Continued




LOD v LOD HLOD a NPL P
D12S1045 (160.7 cM):
All (94) 1.14 .16 6.14 .01 .05 .48 .31
!66 years (50) 1.71 .08 2.44 .17 .19 .72 .23
66 years (44) .00 .50 3.71 .00 .00 .07 .52
!61 years (16) .51 .04 .88 .00 .11 .58 .27
D15S652 (90.0 cM):
All (94) 1.04 .16 1.10 .72 .38 1.23 .11
!66 years (50) .06 .30 2.80 .00 .00 .23 .58
66 years (44) 1.65 .02 1.70 1.76 .81 2.04 .03
!61 years (16) .27 .12 .08 .20 .49 .67 .24
ATA34E08b (33.0 cM):
All (94) .38 .24 3.44 .12 .17 1.30 .10
!66 years (50) .00 .50 4.42 .00 .00 .01 .48
66 years (44) 1.58 .04 .98 1.18 .68 1.89 .03
!61 years (16) .00 .50 1.61 .00 .00 .33 .36
D2S1790 (103.2 cM):
All (94) .29 .26 4.63 .27 .18 .01 .49
!66 years (50) .30 .20 2.21 .22 .22 .18 .56
66 years (44) .04 .32 2.43 .07 .14 .18 .42
!61 years (16) 1.58 .00 .72 .78 .74 .45 .31
a Markers are ordered on the basis of two-point LOD scores in all families; positions are from the Marshfield
map (Broman et al. 1998; also see the Center for Medical Genetics, Marshfield Medical Research Foundation, Web
site). The 16 families with mean age !61 years are a subset of the 50 early-onset families.
b On chromosome 11.
identified, in the earliest-onset group (!61 years), an
∼28-cM region, between D1S468 and GATA29A05, de-
fined by an NPL score 11.75 and with . TheP ! .05
maximum NPL score in this region, 2.28 ( ), wasP = .016
at D1S1612. This NPL score was the largest found in
any analysis of this family set.
Several additional prominent regions ( ) thatP ! .05
were not highlighted by two-point calculations were
found by multipoint analyses of the age strata. In the
44 families with a mean age at diagnosis 66 years,
there was a 19-cM region on chromosome 8p that had
a maximum NPL of 2.02 ( ) at D8S1106 and anP = .026
NPL score of 2.04 ( ) at D15S652. In the 50P = .025
early-onset families, a maximum NPL of 2.06 ( )P ! .03
at D4S2366 identified a 2-cM length with , andP ! .05
an NPL score of 1.93 ( ) at D2S1399 identifiedP = .032
a 2-cM segment of chromosome 2.
Discussion
The findings from our genome scan, which used both
the dominant model and the recessive model in the entire
data set of 94 families, identify several regions of interest,
including regions on chromosomes 1, 8, 10, 12, 14, and
16. None of these meet the usual criteria for significance,
however, and further analysis will be necessary to de-
termine whether these regions truly contain susceptibil-
ity genes. Additional regions were revealed by stratifi-
cations based on age at diagnosis. The most provocative
result found was on chromosome 11, where, for marker
ATA34E08, we observed a LOD score of 3.02 ( )v = .0
and an NPL score of 1.9 ( ) in the 44 later-onsetP = .03
families. Those families in the 66–69-year mean-age
group contributed the majority of the evidence of
linkage.
Interestingly, marker ATA34E08 also defined a lo-
cus of interest in later-onset families in the genome scan
by Suarez et al. (2000). Their analysis involved 504
brothers with prostate cancer who were from 230 mul-
tiplex sibships. A GENEHUNTER-PLUS (Kong and
Cox 1997) likelihood-ratio LOD score (Zlr) score of
1.87 ( ) was found in the 115 families with meanP = .031
age at onset above the 65.4-year median. Together, these
studies suggest that a locus at or near ATA34E08 may
be responsible for some proportion of familial prostate
cancer, particularly in men diagnosed at older ages. This
finding challenges the common paradigm of using early-
onset families to identify cancer-susceptibility loci and
highlights the importance of not limiting the search for
hereditary prostate cancer genes to patients diagnosed
106 Am. J. Hum. Genet. 67:100–109, 2000
Figure 2 Two-point LOD scores of early-onset group (mean age at diagnosis in family !66 years), dominant and recessive models
at young ages. It is possible that the locus at 11p is
associated with less-aggressive disease, which has a
longer preclinical phase and is diagnosed at later ages.
From a public-health standpoint, the 11p locus may
prove to be equally as important as are loci linked solely
to early-onset disease, since the age at diagnosis of the
majority (78%) of patients with clinical prostate cancer
is 165 years (Stanford et al. 1999).
Linkage studies have suggested the locations of four
prostate cancer–susceptibility loci, at 1q24-25 (HPC1),
1q42.2-43 (PCAP), Xq27-28 (HPCX), and 1p36
(CAPB) (Smith et al. 1996; Berthon et al. 1998; Xu et
al. 1998; Gibbs et al. 1999b). All were localized through
analysis of “high risk” families that show an excess of
early-onset disease, compared with the population ex-
pectation. To date, however, no causative gene has been
cloned from any region. Our previous analyses of PRO-
GRESS families found no significant evidence of linkage
to the HPC1 locus at 1q24 (McIndoe et al. 1997; Goode
et al. 2000) and weak evidence of linkage at the 1q42.2-
43 (Gibbs et al. 1999a) and HPCX loci (Peters et al.,
in press). We previously had reported linkage to a pu-
tative new locus at 1p36 (Gibbs et al. 1999b), which
our initial analysis suggested was most important in a
limited group of PROGRESS families with a history of
both prostate and primary brain cancers.
The findings from our genome scan, for both the
dominant model and the recessive model, are consistent
with the studies cited above. In the 94 families studied
here, when the dominant model was used, we did not
detect linkage to HPC1 (maximum positive LOD scores
0). Significant evidence of linkage to the PCAP, HPCX,
and CAPB loci was not seen (LOD scores 0.01–0.39 at
high values of v) in the unstratified data sets. Evidence
of these putative loci is also sparse under the recessive
model, although a LOD score of 1.00 was seen, in the
44 early-onset families, at D1S1660, a marker within
the HPC1 region. Also, a LOD score of 1.99 ( )v = .12
in all 94 families was seen at D1S1656, a marker sit-
uated between theHPC1 and PCAP regions. Multipoint
NPL analysis of all families revealed a peak NPL score
of 1.45 ( ) at marker D1S1597 in the CAPBP = .077
region. This finding was expected, since these PRO-
GRESS families include 7 of the 12 families used to
define the CAPB locus. However, since the evidence for
linkage to this region increased to an NPL score of 2.28
( ) when all very-early-onset families (i.e., with-P = .016
out regard to the presence of brain cancer) were tested,
the detailed phenotypic expression of this gene remains
unclear.
Results from two other genome scans for prostate
cancer loci have been reported. In an analysis of 66
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Figure 3 Two-point LOD scores of later-onset group (mean age at diagnosis in family 66 years), dominant and recessive models
high-risk families, Smith et al. (1996) reported evidence
of linkage to HPC1 and observed LOD scores 11.5 at
only one other marker, D4S430. We saw no evidence
for linkage to markers in that region. In addition to the
11p locus defined by ATA34E08 in later-onset families,
a complete genome scan by Suarez et al. (2000) also
defined areas of interest on chromosomes 2q, 12p, 15q,
16p, and 16q, using an unstratified data set of 230
affected sibships. Stratifications based on family history
of prostate cancer, age at onset, and family history of
breast cancer revealed further regions, including 1p35.1
(in families with a history of breast cancer) and 8q22.3
(in families that meet criteria for “hereditary” prostate
cancer) (Suarez et al. 2000).
Some similar regions were identified between this
study and that of Suarez et al. (2000). The locus on
chromosome 1 is immediately adjacent to the region
that we have identified as containing the putative
CAPB locus (Gibbs et al. 1999b), and, conceivably,
these could be the same. Interestingly, a group includ-
ing one of the authors of the present study has found
data supporting a locus at 1p36 in early-onset fami-
lies but has found no association between this region
and either brain- or breast-tumor history (M. Bad-
zioch, G. Leblanc, R. Eeles, W. D. Foulkes, J. Hopper,
S. Edwards, and D. Goldgar, unpublished data). The
8q22.3 locus that Suarez et al. defined by using marker
GAAT1A4 is ∼16 cM from the locus that we have
defined by using marker D8S2324, where, with the
recessive model, we observed LOD scores of 2.17
( ), in all 94 families, and 2.05, in the familiesv = .10
with age at onset 66 years. However, marker
GAAT1A4 in our analysis showed no evidence of link-
age in either the total or the stratified data sets when
the recessive model was used. Analysis of additional
markers in both data sets may be needed to provide
clarification as to the exact position of this putative
locus.
The strongest signals found by Suarez et al. were for
linkage to broad regions of 16p and 16q, with a peak
multipoint Zlr of 3.15 at D16S3096. We saw no evi-
dence of linkage to 16p when the dominant model was
used, but we did see a LOD score of 1.58 in the total
data set at marker D16S748 when the recessive model
was used. Conversely, we saw the most evidence for
linkage to 16q when the dominant model was used.
Weak positive LOD scores, both in the total data set
(0.31–1.15) and in the later-onset families (0.27–1.44),
were found at four consecutive markers across the 16q
region that was identified by the Suarez et al. study and
that included D16S3096.
It is clear from the work thus far presented by re-
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searchers in this field that, unlike the situation in in-
herited susceptibility to breast cancer, there are more
than two or three major loci that increase susceptibility
to inherited prostate cancer. Successful identification of
prostate cancer–susceptibility loci necessarily will in-
volve categorization or stratification of the data set, to
reduce the complexities associated with locus hetero-
geneity. Avenues currently under pursuit in our ongoing
study, as well as within the field as a whole, include
stratification by clinical features and the organization
of metanalyses with larger data sets for regions sug-
gested by genomewide screens.
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